TRVN — Trevena Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $19.42m
- $3.13m
Brief: Trevena Collaborates With Imperial College London To Test TRV027 In Covid-19
Brief: Trevena Has Received Interest From Multiple Institutions Regarding Potential Studies That Could Evaluate Use Of Trv027 In Covid-19 Patients
Brief: Trevena Reports Q1 Loss Per Share $0.06
Brief: Trevena Announces Publication Of Comprehensive Review Of Oliceridine Data
Brief: Trevena Says On April 17 Received Notice From Listing Qualifications Department Of Nasdaq
Brief: Trevena Pauses Enrollment In Proof-Of-Concept Clinical Trials For Trv250 And Trv734
Brief: Trevena Reports Fourth Quarter And Full Year 2019 Results
Brief: Trevena Says Preliminarily Estimate Of Cash, Cash Equivalents, And Marketable Securities Of About $35.8 Mln As Of Dec. 31, 2019
Brief: Trevena Announces FDA Has Set PDUFA Date Of August 7, 2020 For Oliceridine
Brief: Trevena Says Got Approval From Listing Qualifications Department Of Nasdaq To Transfer Listing Of Co's Stock To Nasdaq Capital Market
Brief: Trevena Resubmits New Drug Application For Oliceridine
U.S. STOCKS ON THE MOVE-Boeing, Tesla, Intra-Cellular Therapies, Seadrill
U.S. STOCKS ON THE MOVE-Apache Corp, Cincinnati Bell, Seadrill, Intra-Cellular Therapies
Trevena rises on initiation of proof-of-concept study for opioid use treatment
Brief: Trevena Announces Initiation Of Proof-Of-Concept Study For TRV734 For Potential Treatment Of Opioid Use Disorder
Brief: Trevena Presents Phase 1 Data On TRV250 For Acute Migraine At American College Of Neuropsychopharmacology 2019 Annual Meeting
Brief: Trevena Says Co, Pfizer Entered Into Amendment To Development & Supply Agreement, Dated Dec. 15, 2016
Brief: Trevena Announces Publication Of Results From Special Population Studies For Oliceridine
Brief: Trevena Reports Q3 Loss Per Share $0.09